Causes of Elevated AST/ALT AND Alkaline Phosphatase
When both aminotransferases (AST/ALT) and alkaline phosphatase (ALP) are elevated simultaneously, you are dealing with a mixed pattern of liver injury that requires systematic evaluation to distinguish between hepatocellular disease with secondary cholestasis, infiltrative liver disease, or concurrent pathologies.
Understanding the Pattern
The pattern of enzyme elevation is determined by the R ratio: (ALT/ULN)/(ALP/ULN) 1, 2:
- Hepatocellular pattern: R ≥5 (aminotransferases predominate)
- Cholestatic pattern: R ≤2 (ALP predominates)
- Mixed pattern: R >2 and <5 (both elevated proportionally)
When you see both AST/ALT and ALP elevated together, calculate the R ratio first—this immediately narrows your differential and guides your workup 2.
Primary Causes by Pattern
Mixed Pattern (R = 2-5)
The most common causes when both are proportionally elevated include:
Common causes:
- Nonalcoholic fatty liver disease (NAFLD) with advanced fibrosis/cirrhosis - prevalence 20-30% in general population, rising to 70% with obesity and 90% with diabetes 1
- Alcohol-induced liver disease - look for AST:ALT ratio >2 (versus <1 in NAFLD) 1
- Drug-induced liver injury - review ALL medications, supplements, and herbals 1, 3
- Chronic viral hepatitis B or C with progression 1
Uncommon causes:
- Autoimmune hepatitis - check ANA, ASMA, IgG levels 4
- Hereditary hemochromatosis - screen with iron studies 1
- Primary biliary cholangitis - particularly if ALP is more elevated 5
Rare causes:
- Wilson disease - especially in patients <40 years, check ceruloplasmin 1
- Alpha-1 antitrypsin deficiency 1
- Infiltrative diseases (sarcoidosis, amyloidosis, lymphoma) 1
Hepatocellular Pattern with Secondary ALP Elevation (R ≥5)
When aminotransferases are markedly elevated with mild ALP elevation:
- Acute viral hepatitis (A, B, C, E, EBV, CMV) 1, 3
- Acute Budd-Chiari syndrome 1
- Ischemic hepatitis (shock liver) 1
- Severe NASH with inflammation 1
- Acute drug-induced liver injury 1, 3
Cholestatic Pattern with Aminotransferase Elevation (R ≤2)
When ALP predominates but aminotransferases are also elevated:
- Biliary obstruction (choledocholithiasis, malignancy, strictures) 1
- Primary biliary cholangitis 5
- Primary sclerosing cholangitis 5
- Infiltrative malignancy with biliary involvement 1
Critical Workup Algorithm
Step 1: Confirm Hepatic Origin of ALP
- If ALP elevated in isolation or disproportionately, confirm hepatic source by checking GGT or fractionating ALP 6, 1
- Non-hepatic ALP sources: bone disease, pregnancy, malignancy
Step 2: Severity Classification
Classify aminotransferase elevation 1:
- Mild: <5× upper limit of normal (ULN)
- Moderate: 5-10× ULN
- Severe: >10× ULN
Step 3: First-Line Laboratory Evaluation
For all patients with elevated AST/ALT and ALP 1, 3, 7:
Viral serologies:
- Hepatitis A IgM, HBsAg, anti-HBc (IgG and IgM), HBV DNA
- Anti-HCV, HCV RNA
- Consider EBV, CMV if acute presentation
Metabolic/toxic screen:
- Comprehensive medication/supplement history
- Alcohol use assessment (AUDIT score)
- Iron studies (ferritin, transferrin saturation, total iron)
- Fasting glucose, HbA1c, lipid panel
- BMI calculation
Autoimmune markers:
- ANA, ASMA (on rodent tissue substrates preferred, or HEp-2 at titer ≥1:80) 4
- Quantitative IgG level 4
Additional tests based on age/presentation:
Step 4: Imaging
Ultrasound abdomen is the first-line imaging modality 1:
- Assesses for steatosis (sensitivity 84.8%, specificity 93.6% for moderate-severe fat)
- Evaluates biliary tree for obstruction
- Identifies masses, cirrhosis features, portal hypertension
Consider advanced imaging (CT/MRI/MRCP) if:
- Ultrasound suggests biliary obstruction
- Concern for infiltrative disease
- Unexplained cholestatic pattern
Step 5: Risk Stratification for Fibrosis
For NAFLD/ARLD patients, calculate fibrosis scores 7:
- FIB-4 score or NAFLD Fibrosis Score (NFS) as first-line
- Consider Fibroscan/elastography if available (refer if >16 kPa) 7
Common Pitfalls to Avoid
Don't assume AST elevation is always hepatic - AST can be elevated from cardiac muscle (MI, myocarditis), skeletal muscle (rhabdomyolysis, myopathy), hemolysis, or even strenuous exercise 1, 8. If AST is disproportionately elevated compared to ALT, check CK and consider non-hepatic sources 6, 3.
Don't overlook macro-AST - persistent isolated AST elevation without other abnormalities may represent macro-AST, a benign condition confirmed by polyethylene glycol (PEG) precipitation 9, 10.
Don't forget to assess synthetic function - albumin and INR/PT are the true markers of liver function, not aminotransferases 1. Normal synthetic function suggests compensated disease.
Don't ignore medication/supplement history - drug-induced liver injury is a common cause and requires exhaustive history including over-the-counter products, herbals, and supplements 1, 3.
Don't use HEp-2 cell ANA/SMA without appropriate cutoffs - if using HEp-2 cells instead of rodent tissue, minimum titer should be 1:80 for diagnostic validity 4.
When to Refer to Hepatology
Immediate/urgent referral 7:
- Synthetic dysfunction (low albumin, elevated INR)
- Jaundice or hyperbilirubinemia
- Features of cirrhosis or portal hypertension
- Severe aminotransferase elevation (>10× ULN)
Routine referral 7:
- Negative extended workup despite persistent abnormalities
- Evidence of advanced fibrosis (FIB-4 >2.67, NFS >0.676, Fibroscan >16 kPa)
- Suspected autoimmune hepatitis (elevated IgG, positive autoantibodies)
- Alcohol dependency (AUDIT >19) with advanced disease
Special Populations
Immune checkpoint inhibitor patients: Monitor AST, ALT, and bilirubin before each infusion. Grade ≥2 hepatotoxicity (AST/ALT >3-5× ULN) requires holding therapy and workup for competing causes including viral hepatitis, tumor progression, and other drug toxicity 6, 3.
Pregnant patients: Elevated aminotransferases with ALP in third trimester should prompt evaluation for intrahepatic cholestasis of pregnancy, with ALT and ALP being the strongest predictors 11.